34 results about "Protoporphyrin IX" patented technology

The invention belongs to the technical field of gas sensors, and discloses a portable ratio fluorescent film sensor for visual detection of oxygen as well as a preparation method and application of the portable ratio fluorescent film sensor. According to the sensor, polymethyl methacrylate is used as a base material, a carbon dot emitting blue light is used as a fluorescent indicator, protoporphyrin emitting red light is used as a fluorescent reference agent, and the two materials are physically blended to form a blue-red dual-emission system; under the excitation of 365nm ultraviolet light, the oxygen concentration affects the yield of active oxygen, the active oxygen quenches the fluorescence of the carbon dots, the fluorescence of protoporphyrin is stable, and the sensor gradually changes from blue violet to red. Meanwhile, the invention discloses an oxygen quantitative / semi-quantitative detection method of the sensor. The preparation process is simple, the cost is low, the detection operation is simple and convenient, the anti-interference performance is strong, the high-sensitivity visual portable detection of the oxygen concentration can be realized, and the sensor is suitable for the fields of food packaging, medical monitoring, industrial safety and the like, and has the potential of large-scale production and commercial application.

The invention discloses a detection kit based on orthogonal dual-channel label-free CRISPR-Cas and application of the detection kit, relates to the technical field of nucleic acid detection, and constructs an orthogonal dual-channel response system by utilizing the differentiated cleavage activity of Cas12a targeted DNA and Cas13 targeted RNA to a substrate. A Cas12a pathway is reported by utilizing protoporphyrin IX to be compounded with G-quadruplex G4DNA, and a Cas13a pathway is reported by utilizing DFHBI to be compounded with a Broccoli RNA structure, so that label-free signal transduction is realized. Through accurate screening of fluorophores, channel specificity is ensured, and optical signal crosstalk is eliminated. Mycobacterium tuberculosis (MTB) and respiratory syncytial virus (RSV) are used as model pathogens for verification, and a multiple recombinase polymerase amplification (RPA) technology is combined, so that the detection sensitivity on a synthetic target reaches a single molecule level. The system has high specificity, and even if the concentration of a non-target pathogen is increased by 100 times, no cross reaction exists.

Here, the inventors have developed a spectral flow cytometry assay to measure heme biosynthesis. By using this new assay on melanoma cell lines, they observed a direct correlation between high PPIX levels in differentiated MITFhigh cells and a protection against ferroptosis. Conversely, cell lines with low PPIX levels were associated with a dedifferentiated MITFlow phenotype enriched in stem cell markers and more sensitive to ferroptosis inducers. They also found that inhibition of PPIX biosynthesis in differentiated melanoma cells synergizes with iron overload to induce lipid peroxidation and tumor cell death. Finally, they show that decreased levels of PPIX linked to increased ferroptosis sensitivity can be acquired in vivo in melanoma tumors that relapse after anti-MAPK targeted therapies. The present invention relates to a method of determining whether a subject has or is at risk of having melanoma ferroptosis sensitivity and targeted therapy resistance comprising i) determining the level of protoporphyrin IX (PPIX) in a biological sample obtained from the subject and ii) comparing the level determined at step i) with a predetermined reference value: wherein if the level of the PPIX determined at step (i) is lower than the predetermined reference value is indicative that the said patient is having melanoma ferroptosis sensitivity and targeted therapy resistance or wherein if the level of the PPIX determined at step (i) is higher than the predetermined reference value is indicative that the said patient is having melanoma ferroptosis resistance and targeted therapy sensitivity. The present invention also relates to a method for treating resistant melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a ferroptosis inducer.

The present invention relates to a compound of formula (I) or a salt thereof, wherein the group R is as defined in the specification; and also relates to a method for preparing the compound and its use as a photosensitizer in photodynamic therapy. The monosubstituted protoporphyrin derivatives involved in the present invention all have high permeability, high activity, and good biosafety. The preparation method is simple, low-cost, and can obtain the target product in good yield. It is particularly suitable for industrial production and can be used as a highly effective photosensitizer in photodynamic therapy to treat oral diseases such as periodontitis, gingivitis, dental plaque, and caries caused by Gram-negative anaerobic cocci and other bacteria such as Porphyromonas gingivalis.

The present invention relates to a fluorescence observation system, to a method for carrying out a fluorescence observation and to a filter set that can be used for this purpose for simultaneously observing fluorescent light of protoporphyrin IX in an object and non-fluorescent regions of the object in an almost true-colour representation. The filter set comprises an illumination filter and an observation filter. A transmittance of the illumination filter has an average value of at least 90% from 405 nm to 452 nm, is at most 0.01% in at least 95% of a wavelength range extending from 466 nm to 524 nm, has an average value of at least 0.028% and at most 0.044% from 535 nm to 595 nm, and is at most 0.003% in at least 95% of a wavelength range extending from 610 nm to 750 nm. A transmittance of the observation filter has an average value of at least 0.143% and at most 0.187% from 404 nm to 438 nm, is at most 0.01% in at least 95% of a wavelength range extending from 444 nm to 534 nm, and has an average value of at least 90% from 544 nm to 722 nm.

A method to make Co- or Ni-substituted protoporphyrin IX by incubating an E. coli strain in a rich medium containing iron ions and added Co2+ or Ni2+ ions, for a time and under conditions wherein the E. coli strain produces Co- or Ni-substituted protoporphyrin IX. The E. coli host may be transformed to contain and express a gene construct encoding a mutant EcHemH including a L13R mutation.

The present invention relates to a compound of formula (I) or a salt thereof, wherein the group R is as defined in the description; the invention also relates to a preparation method of the compound and application of the compound as a photosensitizer in photodynamic therapy. The mono-substituted protoporphyrin derivative has high permeability, high activity and good biological safety, the preparation method is simple in process and low in cost, a target product can be obtained with good yield, and the mono-substituted protoporphyrin derivative is especially suitable for industrial production and has wide application prospects. The compound can be used as an efficient photosensitizer for treating hyperproliferative diseases such as cancers or precancerous lesions in photodynamic therapy, or treating oral diseases # imgabs0 # (I) such as periodontitis, gingivitis, dental plaque and decayed teeth caused by bacteria such as Gram-negative anaerobic bacillus such as porphyromonas gingivalis.

The invention belongs to the technical field of biological medicine, and discloses a prodigiosin (PG) and tannic acid (TA) self-assembled carrier-free nano-particle as well as preparation and application thereof. The particles are formed by PG and TA through nano-precipitation self-assembly, and the particle size is 30-50 nm. The preparation method comprises the following steps: respectively dissolving PG and TA in DMSO, mixing and stirring according to a molar ratio of (5-10): 1, dropwise adding ddH2O, carrying out ultrasonic treatment, dialyzing to remove a solvent, centrifuging, taking precipitate, and freeze-drying to obtain powder. The nanoparticles can efficiently kill methicillin-resistant staphylococcus aureus and other multi-drug-resistant bacteria, remove excessive ROS, inhibit TNF-alpha, IL-1beta and IL-6 and promote expression of IL-4, IL-10 and TGF-beta, so that infected skin flap necrosis is relieved, skin repair is promoted, and the nanoparticles have good biological safety and can be used for preparing antibacterial and infected wound treatment drugs.

The application belongs to the technical field of biomedicine, and particularly relates to a CuTA-Por@epsilon-PL nano platform and a preparation method and application thereof. The nano platform is prepared by grafting protoporphyrin (Por) through amidation reaction of CuTA, and wrapping the CuTA by epsilon-polylysine (epsilon-PL) through electrostatic adsorption, so as to synthesize CuTA-Por@epsilon-PL NPs (CPP NPs), which can be used as a potential treatment method for treating peri-implantitis, destroying bacterial biofilm and regulating inflammation.

The present invention relates to a compound of formula (I) or a salt thereof, wherein the group R is as defined in the description; the invention also relates to a preparation method of the compound and application of the compound as a photosensitizer in photodynamic therapy. The mono-substituted protoporphyrin derivative has high permeability, high activity and good biological safety, the preparation method is simple in process and low in cost, a target product can be obtained with good yield, and the mono-substituted protoporphyrin derivative is especially suitable for industrial production and has wide application prospects. The compound can be used as a high-efficiency photosensitizer for treating oral diseases # imgabs0 #, such as periodontitis, gingivitis, dental plaque, decayed teeth and the like, caused by bacteria such as Gram-negative anaerobic bacillus, such as porphyromonas gingivalis in photodynamic therapy.

The invention relates to a method and a sensor for detecting and / or quantifying a set of hematological parameters in a blood or derived biological fluid sample, the set of hematological parameters comprises at least one parameter selected from the group consisting of the number (RC) of a blood cell component in the blood or derived biological fluid, the average blood cell volume (MCV) of said blood cell component, the percentage (HCT) of the blood cell component in the sample volume and the amount of at least one substance (Hb) comprising a protoporphyrin metal complex. The invention also relates to a method for producing the electrical analysis sensor.

The invention belongs to the technical field of biological pharmacy, and particularly discloses an application of protoporphyrin IX in preparation of an anti-akabane virus drug. By measuring the safe concentration range of the protoporphyrin IX on MDBK cells and through RT-qPCR, WB, IFA and TCID50, it is found that the protoporphyrin IX can serve as an inhibitor of AKAV viruses, when the concentration of the protoporphyrin IX is 10 [mu] M, the protoporphyrin IX has a remarkable inhibition effect on the AKAV viruses, and the application of the protoporphyrin IX in preparation of the anti-akabane virus drug in preparation of the anti-akabane virus drug in preparation of the anti-akabane virus drug in preparation of the anti-akabane virus drug is achieved. And a new candidate medicine is provided for preventing and treating AKAV virus infection.

This invention provides an in-situ gel delivery carrier for 5-aminolevulinic acid and its preparation method, belonging to the field of biomedical technology. The in-situ gel delivery carrier comprises TAT ​​peptide and *Rhizopus oryzae* lipase; the mass-to-volume ratio of TAT peptide to *Rhizopus oryzae* lipase is 0.03-0.07 g: 0.005-0.015 g. This in-situ gel delivery carrier combines a dual mechanism of "physical thermosensitive phase transition" and "biological thermosensitive enzyme activity" to achieve long-term, targeted adhesion to lesion sites. Through the nonlinear synergistic effect of *Rhizopus oryzae* lipase and TAT peptide, it precisely degrades lipid barriers and efficiently delivers drugs, thereby significantly reducing the drug concentration while exponentially increasing the conversion efficiency of protoporphyrin IX (PpIX) in target cells. The preparation method is simple to operate.

The present invention relates to a compound of formula (I) or a salt thereof, wherein the group R is as defined in the description; the invention also relates to a preparation method of the compound and application of the compound as a photosensitizer in photodynamic therapy. The mono-substituted protoporphyrin derivative has high permeability, high activity and good biological safety, the preparation method is simple in process and low in cost, a target product can be obtained with good yield, and the mono-substituted protoporphyrin derivative is especially suitable for industrial production and has wide application prospects. The compound can be used as an efficient photosensitizer for treating hyperproliferative diseases such as cancers or precancerous lesions in photodynamic therapy, or treating oral diseases # imgabs0 # such as periodontitis, gingivitis, dental plaque and decayed teeth caused by bacteria such as Gram-negative anaerobic bacillus such as porphyromonas gingivalis.

The present invention relates to compounds of formula (I) or salts thereof, wherein the group R is as defined in the specification; and methods for preparing the compounds and their use as photosensitizers in photodynamic therapy. The monosubstituted protoporphyrin derivatives disclosed herein all exhibit high permeability, high activity, and good biosafety. Their preparation methods are simple, cost-effective, and capable of obtaining the target product in good yield, making them particularly suitable for industrial production. They can be used as highly effective photosensitizers in photodynamic therapy to treat hyperproliferative diseases such as cancer or precancerous lesions, or to treat oral diseases such as periodontitis, gingivitis, dental plaque, and dental caries caused by Gram-negative anaerobic cocci and other bacteria, such as Porphyromonas gingivalis.

The present invention relates to a fluorescence observation system, a method for performing fluorescence observation, and a filter set usable therefor for the simultaneous observation of fluorescent light from protoporphyrin IX in an object and of non-fluorescent areas of the object in a nearly color-accurate representation. The filter set comprises an illumination filter and an observation filter. The transmittance of the illumination filter has an average value of at least 90% from 405 nm to 452 nm, is at most 0.01% in at least 95% of a wavelength range extending from 466 nm to 524 nm, has an average value of at least 0.028% and at most 0.044% from 535 nm to 595 nm, and is at most 0.003% in at least 95% of a wavelength range extending from 610 nm to 750 nm.The transmittance of the observation filter has an average value of at least 0.143% and at most 0.187% from 404 nm to 438 nm, is at most 0.01% in at least 95% of a wavelength range extending from 444 nm to 534 nm, and has an average value of at least 90% from 544 nm to 722 nm.

This invention relates to a compound and its preparation method, a modular peptide nanovaccine and its preparation method and application, and relates to the pharmaceutical field. The chemical structural formula of the compound is shown in Formula I. This invention provides a compound containing an mPEG-PLA structure, a protoporphyrin structure chelated with cobalt ions, and a β-cyclodextrin structure, endowing it with excellent binding ability to peptides and excellent loading capacity with adjuvants, achieving co-delivery of peptides and adjuvants. Based on this, this invention also provides a modular peptide nanovaccine with high peptide loading rate and "plug-and-play" characteristics. It can significantly inhibit tumor growth in a B16 subcutaneous tumor model, providing an efficient and flexible technical platform for the prevention of melanoma and other tumors and the clinical translation of peptide vaccines, with broad application prospects.

The invention discloses a multifunctional feed additive for improving yolk chromaticity and whole egg quality, and belongs to the technical field of feed additives. The additive is prepared by mixing the following dry substances in parts by weight: 300-500 parts of pine needle meal, 100-150 parts of hermetia illucens powder, 2-8 parts of cantharides yellow, 0.5-5 parts of protoporphyrin and 0.3-1 part of vitamin E. The feed additive disclosed by the invention is added into daily ration of laying hens at the dosage of 1-5%, so that the chromaticity of egg yolk can reach 11-12 grades, the egg yolk is still effective after 10 days after the addition is stopped, the feed additive is obviously superior to an existing single or binary compound colorant, and meanwhile, the egg shell strength is improved, the Hough unit is increased, and the problem of quality decline of eggs laid by the laying hens in the later period of egg laying is solved. The technical problems that an existing egg yolk coloring agent is single in function, short in coloring effect lasting time and incomplete in egg quality improvement are solved, and the egg yolk coloring agent has safety, economical efficiency and practicability.

The present invention discloses a multifunctional ratio fluorescence probe, which is mainly obtained by the coupling reaction of a metal-organic framework material Uio-66-NH2 and protoporphyrin. The preparation method may include the following steps: Step 1, synthesis of the metal-organic framework material Uio-66-NH2; Step 2, preparation of a protoporphyrin stock solution; Step 3, coupling action of Uio-66-NH2 and protoporphyrin. The multifunctional fluorescence probe of the present invention is simple to prepare, has a very significant fluorescence response to acidity and alkalinity, has an obvious visual effect under the irradiation of a 365 nm ultraviolet lamp, and is easy to distinguish. In addition, the probe can realize highly sensitive reversible detection of copper ions and sulfide ions, and has the advantages of high selectivity, rapid detection, strong practicability, etc., providing a potential application prospect for the rapid detection of target substances in the water environment.

A method for performing photodynamic therapy is provided. The method includes applying a topical composition to the skin of a patient. The topical composition includes 5-aminolevulinic acid (ALA) hydrochloride and a vehicle including at least one chelating agent for enhancing accumulation of protoporphyrin IX (PpIX) in the skin. The method further includes incubating the topical composition and, after incubation, applying heat from a heat source to the skin for at least a first period of time.

While clinical treatment of actinic keratosis by photodynamic therapy (PDT) is widely practiced, there is well-known variability in response, primarily caused by heterogeneous accumulation and PDT-induced photobleaching of the photosensitizer protoporphyrin IX (PpIX) between patients and between lesions. One of the key factors in regularizing this treatment would be to have an easily accessible indicator of PpIX present in the lesions at the time of light delivery. Described herein, a smartphone-based fluorescence imager was developed to allow simple quantitative photography of the lesions and their PpIX levels.

The present invention relates to a compound of formula (I) or a salt thereof, wherein the group R is as defined in the specification; it also relates to a method for preparing the compound and its use as a photosensitizer in photodynamic therapy. All the monosubstituted protoporphyrin derivatives involved in the present invention have high permeability, high activity and good biosafety. The preparation method has simple process, low cost, can obtain the target product in good yield and is particularly suitable for industrial production. It can be used as an efficient photosensitizer for treating hyperplastic diseases such as cancer or precancerous lesions in photodynamic therapy, or treating oral diseases such as periodontitis, gingivitis, dental plaque and dental caries caused by bacteria such as Gram-negative anaerobic coccobacilli like Porphyromonas gingivalis (I).

An image capture apparatus for capturing an image of an object of medical interest in reemitted and / or reflected illumination light, for capturing an image of the object in fluorescence light generated by protoporphyrin, and for capturing an image in fluorescence light generated by OTL38. The apparatus includes an image sensor for capturing blue, green and red light, another image sensor for capturing fluorescence light from protoporphyrin and OTL38, and a beam splitter for guiding light from the object that has a wavelength shorter than a predetermined threshold wavelength λ0 to the first image sensor, and for guiding light from the object that has a wavelength longer than the predetermined threshold wavelength λ0 to the second image sensor. A filter arranged upstream of the second image sensor partially, extensively or completely suppresses light at a wavelength suitable for exciting fluorescence of OTL38. A corresponding method is also presented.

The present invention discloses a checkerboard-style flexible sensing patch, its preparation method, and application. The material comprises a checkerboard array of intermittently arranged photothermal therapy modules excited by near-infrared I light and bacterial detection modules excited by near-infrared II light. The photothermal therapy modules are prepared by grafting polyethyleneimine onto the surface of carboxylated nanofiber crystals via an amidation reaction, followed by grafting protoporphyrin zinc onto the surface of the polyethyleneimine via an amidation reaction. The bacterial detection modules are prepared by integrating amino-functionalized upconversion nanoparticles and thermosensitive detection micelles onto cellulose nanofiber crystals. This patch can detect bacterial levels in infected wounds and kill bacteria under near-infrared light excitation.

Provided are methods of isolating or extracting human mitochondrial tryptophan-rich sensory protein (HsTSPOl). The methods include contacting the H.sTSPOl with an effective amount of at least one Native Cell Membrane Nanoparticle (NCMN) polymer and recovering the TSPO. Compositions containing TPSO encapsulated in a particle formed by the NCNM polymer are also provided. A protoporphyrin derivative compound, methods of producing bilindigin or derivatives thereof, and methods of screening compounds that modulate TSPO activity are also provided.

Filter set, including: an illumination light filter (84) and an observation light filter (91), wherein a transmission characteristic (105) of the illumination light filter (84) is a sum of a first partial characteristic (I) and a second partial characteristic (II), wherein the transmission of the first partial characteristic (I) within a first wavelength range (109) which lies below a cut-off wavelength (107) is greater than a first value (L1); wherein the transmission of the second partial characteristic (II) within a second wavelength range (111) which lies above the cut-off wavelength (107) is less than a second value (L2) and greater than a third value (L3), wherein a transmission characteristic (113) of the observation light filter (91) is a sum of a third partial characteristic (III) and a fourth partial characteristic (IV), wherein the transmission of the third partial characteristic (III) within a third wavelength range (115) which lies above the cut-off wavelength (107) is greater than the first value (L1); wherein the transmission of the fourth partial characteristic (IV) within a fourth wavelength range (117), which lies below the cut-off wavelength (107), is smaller than the second value (L2) and larger than the third value (L3), wherein the transmission of the illumination light filter (84) within a fifth wavelength range (118) which lies between the first wavelength range (109) and the second wavelength range (111) is less than a fourth value (L4); wherein the transmission of the observation light filter (91) within a sixth wavelength range (119) which lies between the third wavelength range (115) and the fourth wavelength range (117) is smaller than the fourth value (L4); where the fourth value (L4) is smaller than the third value (L3), the third value (L3) is smaller than the second value (L2) and the second value (L2) is smaller than the first value (L1), where the cutoff wavelength (107) is between 450 nm and 550 nm, wherein the first wavelength range (109) lies between 350 nm and the cutoff wavelength, wherein the second wavelength range (111) lies between the cutoff wavelength and 620 nm and is at least 50 nm wide, wherein the third wavelength range (115) lies between the cutoff wavelength and 800 nm, wherein the fourth wavelength range (117) lies between 410 nm and the cutoff wavelength.

A system for imaging of oxygen concentration in tissue or diffuse media using a protoporphyrin IX fluorophore probe includes a pulsed excitation light to stimulate fluorophore and a gated electronic camera synchronized to the pulsed light. The gated electronic camera captures immediate fluorescence images in an immediate fluorescence time window overlapping a light pulse from the pulsed light source and delayed fluorescence images after a light pulse. An image processor receives the immediate and delayed fluorescence images from, the image processor producing images indicative of tissue oxygenation therefrom. In another embodiment, a method of generating oxygen level images of tissue includes using a pulsed excitation light illuminator and a gated camera to obtaining immediate and delayed fluorescence images of the tissue. The method includes determining a ratio image from the delayed fluorescence image and the immediate fluorescence image, the ratio image providing an oxygen level image of the tissue.

A composition comprising Protoporphyrin IX (PpIX) or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient or a TauT inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein preferably the excipient is a carrier or a diluent.

The invention relates to the technical field of medicine application, in particular to application of protoporphyrin IX in medicine for inhibiting porcine reproductive and respiratory syndrome virus. The PpIX has a remarkable antiviral effect on porcine reproductive and respiratory syndrome virus infection, can be used for preparing anti-PRRSV drugs, provides a reliable basis for treatment and prevention and control of diseases caused by the virus, and provides a new thought and an effective coping strategy for prevention and control work of PRRSV. The research also discovers the optimal action mode of PpIX for inhibiting PRRSV proliferation and the period of PRRSV replication, and a theoretical basis is provided for prevention and control of PRRS.

The invention discloses a group of serum exosome metabolism markers for identifying SLE (systemic lupus erythematosus) and nephritis implication, wherein the serum exosome metabolism markers comprise one or more of Pro-Asn-Gln-Met-Ser, C24: 1 spingolipid and protoporphyrin IX. The invention further discloses a kit for identifying the SLE and the nephritis implication, and the kit for identifying the SLE and the nephritis implication comprises one or more of the Pro-Asn-Gln-Met-Ser, the C24: 1 spingolipid and the protoporphyrin IX. The invention provides three serum exosome metabolic markers, namely Pro-Asn-Gln-Met-Ser, C24: 1 spingolipid and protoporphyrin IX, which are high in sensitivity and strong in specificity, and the serum exosome metabolic markers can be used for identifying the systemic lupus erythematosus and distinguishing whether the systemic lupus erythematosus has lupus nephritis or not. According to the invention, the identification accuracy can be further improved, timely early warning can be realized clinically, and new standards for clinical identification of systemic lupus erythematosus can be determined.